Mylan stock dropped 7% after second quarter sales slumped (MYL)

Screen Shot 2018 08 08 at 9.37.07 AM

  • Mylan’s stock dropped 7.4% shortly after markets opened on Wednesday due to poor second quarter earnings.
  • The company’s total revenue for the second quarter was $2.8 billion, down 5% compared to last year. Sales in North America also fell 22%. 
  • Mylan then announced that it was going to conduct a strategic review of the company, saying it believes it is undervalued. This means the company could be broken up or sold. 
  • Mylan N.V. is an American pharmaceutical company registered in the Netherlands that makes both generic and specialty drugs. It is best known as the manufacturer of EpiPen. 

SEE ALSO: Ovid Therapeutics shares fall 28% as investors question new drug data

Join the conversation about this story »

NOW WATCH: Super-Earths are real and they could be an even better place for life than Earth

Source: Business insider

Kommentar verfassen